ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO897

Influence of Therapeutic Drugs on Different Manifestations of Renal Involvement in 907 Chinese Patients with Ankylosing Spondylitis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Xue, Qin, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
  • Wu, Yan, Shanghai University of Medicine & Health Sciences Affiliated East Branch of Sixth People's Hospital, Shanghai, China
Background

Studies on renal involvement in AS are at the initial stage, and hardly we see systematic and large-scale study on the relationship between therapeutic drugs and renal involvement in AS patients. Moreover, the drug sensitivity of kidney varies significantly from races and regions. Therefore, the aim of this study is to investigate the impacts of therapeutic drugs on renal involvement in Chinese AS patients.

Methods

The clinical characteristics and biochemical data of the patients were collected and analyzed. The differences in clinical and laboratory characteristics between the drug and drug-free patients were calculated by Inter-group comparison to screen out confounding factors. Then the multivariate logistic regression analysis with correcting confounding factors was carried out to explore the impacts of the drugs on the renal involvement according to clinical manifestations.

Results

A total of 907 patients were enrolled in the study, 232(26%) patients suffered from renal involvement. Among them, there were 149/232(64%) hematuria, 55/232 (24%) proteinuria, and 27/232 (12%) patients with multiple clinical manifestations. 21/232 underwent a renal biopsy to determinate renal pathology. 363/907 (40%) of the patients received therapy: 92(25%) NSAIDs monotherapy, 88(24%) csDMARDs monotherapy, 27(8%) TNF-α inhibitor monotherapy, and 156(43%) combination of the drugs. The probability of renal involvement in Chinese AS patients increased significantly in NSAIDS or csDMARDs monotherapy, and combination therapy of NSAIDs, csDMARDs and TNF-α inhibitor. For AS patients, NSAIDs monotherapy increased the probability of hematuria by 2.4 times, and the probability of mixed manifestations of renal involvement by 3.0 times; csDMARDs monotherapy increased the probability of proteinuria by 2.4 times; combination therapy of NSAIDs, csDMARDs and TNF-α inhibitor increased the probability of hematuria by 4.1 times. In addition, the study found that TNF-α inhibitor monotherapy and its combination therapy with NSAIDs or csDMARDs had no obvious impact on renal involvement in AS patients.

Conclusion

NSAIDs or csDMARDs monotherapy may significantly increase renal involvement in AS patients. The combination therapy of TNF-α inhibitor with NSAIDS and csDMARDs should be used prudently. Renal involvement should be closely observed during the treatment.

Funding

  • Clinical Revenue Support